Search research articles
Contact Us
Filters
Showing results (431-440 of 524) with videos related to
Page
of 53
Sort By:
Cancer Discovery
|
April 4, 2018
Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i>-Rearranged Cancers
Alexander Drilon, Romel Somwar, Biju P Mangatt, et al.
The New England Journal of Medicine
|
June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Giannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.
Science Translational Medicine
|
August 2, 2023
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers
Alvaro Quintanal-Villalonga, Vidushi Durani, Amin Sabet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2013
Characteristics of lung cancers harboring NRAS mutations
Kadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.
Cancer Discovery
|
September 25, 2021
<i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung
Carla P Concepcion, Sai Ma, Lindsay M LaFave, et al.
JCO Precision Oncology
|
November 20, 2025
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms
Rohit Thummalapalli, Salomon Tendler, Joanne F Chou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2012
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer
Charles M Rudin, Christine L Hann, Edward B Garon, et al.
Lancet (London, England)
|
December 17, 2023
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
Chiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, et al.
Cancer Research
|
November 24, 2021
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J K Sabari, G C Leonardi, C A Shu, et al.
Page
of 53
Search research articles
Search
Showing results (431-440 of 524) with videos related to
Sort By:
Page
of 53
Cancer Discovery
|
April 4, 2018
Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i>-Rearranged Cancers
Alexander Drilon, Romel Somwar, Biju P Mangatt, et al.
The New England Journal of Medicine
|
June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Giannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.
Science Translational Medicine
|
August 2, 2023
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers
Alvaro Quintanal-Villalonga, Vidushi Durani, Amin Sabet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2013
Characteristics of lung cancers harboring NRAS mutations
Kadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.
Cancer Discovery
|
September 25, 2021
<i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung
Carla P Concepcion, Sai Ma, Lindsay M LaFave, et al.
JCO Precision Oncology
|
November 20, 2025
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms
Rohit Thummalapalli, Salomon Tendler, Joanne F Chou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2012
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer
Charles M Rudin, Christine L Hann, Edward B Garon, et al.
Lancet (London, England)
|
December 17, 2023
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
Chiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, et al.
Cancer Research
|
November 24, 2021
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J K Sabari, G C Leonardi, C A Shu, et al.
Page
of 53